Acyclovir Capsule
Product Images NDC 68071-2299

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Acyclovir (NDC 68071-2299). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2299 3)

This appears to be a product description for Acyclovir 200mg capsules sold by NuCare Pharmaceuticals, Inc. The product contains 30 capsules and is only available via prescription. It is oval, opaque, and light blue in color. The warnings on the label advise users to keep the product out of reach of children and to report side effects to the FDA. The capsules should be stored in a controlled environment at a temperature between 68-77°F. The product has a lot number of 000000 and a GTIN of 00368071229936. However, some of the text is not readable, and the information provided is limited.*

FDA Label Image

Structural Formula (Acy03 0000 01)

FDA Label Image

Table 1 (Acy03 0000 02)

Table 1 presents the pharmacokinetic characteristics of Acyclovir, which is a medication used to treat herpes virus infections. The table shows the range for different parameters such as plasma protein binding and plasma elimination half-life. The average oral bioavailability ranges from 10% to 20%, with a decrease in bioavailability as the dose increases.*

FDA Label Image

Table 2 (Acy03 0000 03)

This text provides information on the peak and trough concentrations of Acyclovir at steady state for different dosages (200mg, 400mg, and 800mg). It includes the concentration values for both peak (Coax) and trough (Cirough) levels.*

FDA Label Image

Table 3 (Acy03 0000 04)

Table 3 shows the dosage modification for patients with different levels of renal impairment. The table gives the normal dosage alongside the adjusted dosage regimen for individuals with creatinine clearance of less than or greater than 10 mL/min/1.73 m2 or between 10-25 mL/min/1.73m2. The adjusted dosages vary based on the level of renal impairment, and the dosages range from 200mg to 800mg every 4 hours, 5 times a day, or every 12 hours, depending on the patient's condition.*

FDA Label Image

Imprint Cti 114 (Acy03 0000 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.